Replies to post #5672 on InVivo Therapeutics Holdings Corp (NVIVQ)

[north40000]

Very creative SEC document. Dew thought it was April 1, 2017 and an April fools' joke:

PXRB seeks to acquire NVIV for $2.40/sh— ~ 44% discount to the current price:

"Justification for NVIV Take-under at $77,000,000



· NVIV lacks Frank Reynolds Patent rights to commercialize the NeuroScaffold, the probability of a deal is zero under current Board of Directors and CEO
· Frank Reynolds has rejected NVIV request to assign rights to Neuroscaffold patent
· NVIV never compensated Frank Reynolds with shares for his inventions, and NVIV expects the use of the Neuroscaffold patents for free, but there will be a cost, and that cost must be factored into the current NVIV valuation, setting the new valuation around $77,000,000
· Since Reynolds resigned in 2013, NVIV CEOs twice have managed the stock down to Frank Reynolds’ 2010 IPO price, CEO Mark Perrin has got to resign "